In the ongoing human effort to outpace the slow erosion of cardiovascular disease, a large real-world study has offered meaningful evidence that tirzepatide — a dual-action diabetes medication — may do more than manage blood sugar. Analyzing insurance records from over 52,000 patients across the United States, researchers found that those with type 2 diabetes and existing heart disease who took tirzepatide experienced roughly a third fewer major cardiovascular events than those on sitagliptin, a drug known to be heart-neutral. The finding, published in The BMJ, does not close the conversation
Tirzepatide cuts major cardiovascular events by 32% in type 2 diabetes patients
The signal is compelling; the causal questions remain open.
Mark
Why compare tirzepatide to sitagliptin specifically? Why not just measure it against doing nothing?
Mimi
Because you need a fair comparison. Sitagliptin was chosen precisely because earlier research showed it doesn't affect heart outcomes one way or the other—it's a neutral baseline. If you compared tirzepatide to no treatment, you couldn't tell if the benefit came from tirzepatide itself or just from treating diabetes better.
Mark
So this is observational data, not a randomized trial. How much should we trust it?
Mimi
That's the right skepticism. Observational studies can't prove causation the way trials can. But these researchers had validated their methods against actual randomized trials beforehand. They also adjusted for dozens of factors—age, prior heart disease, other medications—to make the two groups as comparable as possible. It's not perfect, but it's more reliable than it might first appear.
Mark
The stroke numbers are interesting. Why would tirzepatide prevent heart attacks but not strokes?
Mimi
That's genuinely unclear from this data. It could be that the drug works through different mechanisms for different types of events. Or it could be that one year simply isn't long enough to see a stroke benefit. Or the sample size for strokes might have been too small to detect a real difference. That's exactly the kind of question longer studies need to answer.
Mark
One MACE prevented per 70 patients treated—is that good?
Mimi
In cardiology, yes. That's a meaningful reduction. But it also means 69 people get the drug without preventing a major event in that year. That's why the editorial raises the practical point: if the drug is expensive, hard to get approved by insurance, or causes side effects that make people quit, those benefits disappear. The signal is real, but real-world obstacles matter as much as the science.
Mark
What happens after one year?
Mimi
Nobody knows yet. This study stopped tracking at one year. We don't know if the benefit grows, stays the same, or shrinks over time. We don't know about rare side effects that only show up after years of use. That's why the researchers are calling for longer follow-up. The short window is both a strength—the data is recent and clear—and a weakness.
The Pulse
- For millions of people living with both type 2 diabetes and heart disease, the question of which medication offers the best protection has long carried life-or-death weight — and this study sharpens that question considerably.
- Tirzepatide cut major cardiovascular events from 4.4% to 2.9% compared to sitagliptin, with one serious event prevented for every 70 patients treated — a margin that clinicians and regulators cannot easily set aside.
- Beyond the heart, the drug also reduced hospital infections, infection-related deaths, and all-cause mortality, though it showed no meaningful advantage over sitagliptin in preventing stroke specifically.
- Because this was an observational study drawn from insurance claims rather than a controlled trial, the findings establish a strong association but stop short of proving causation — a distinction that shapes how confidently doctors can act on them.
- Even where the science is compelling, real-world barriers loom: high costs, insurance authorization hurdles, supply gaps, and treatment discontinuation all threaten to keep the drug's benefits out of reach for the patients who need it most.
In the ongoing human effort to outpace the slow erosion of cardiovascular disease, a large real-world study has offered meaningful evidence that tirzepatide — a dual-action diabetes medication — may do more than manage blood sugar. Analyzing insurance records from over 52,000 patients across the United States, researchers found that those with type 2 diabetes and existing heart disease who took tirzepatide experienced roughly a third fewer major cardiovascular events than those on sitagliptin, a drug known to be heart-neutral. The finding, published in The BMJ, does not close the conversation about how and when to use the drug, but it places a clearer marker in the long search for treatments that protect the heart as well as they manage the condition that threatens it.
A study published in The BMJ has found that tirzepatide, the diabetes drug sold as Mounjaro, reduces the risk of major cardiovascular events by nearly a third in people with type 2 diabetes who already have heart disease. Drawing on insurance claims data from more than 52,000 patients treated between 2022 and 2025, the research offers one of the most detailed real-world pictures yet of how the medication performs outside a clinical trial setting.
Researchers compared tirzepatide against sitagliptin — a diabetes drug established to have no particular effect on heart health — making it a useful benchmark. After adjusting for age, sex, weight, prior heart conditions, and other variables, 2.9% of tirzepatide patients experienced a major cardiovascular event over one year, compared to 4.4% in the sitagliptin group. That translates to one prevented event for every 70 patients treated. Heart attack risk fell by 33%, though stroke rates showed no meaningful difference between the two groups.
The drug's benefits extended beyond the cardiovascular system. Tirzepatide was also associated with fewer hospital admissions for infection, fewer infection-related deaths, and lower all-cause mortality — with one death from any cause prevented for every 122 patients treated.
The authors were candid about the study's limits. The one-year follow-up may miss longer-term effects, and as an observational study, it can demonstrate association but not causation. The findings may also not apply to patients without established heart disease or to healthcare systems outside the US. An editorial accompanying the study welcomed the evidence while noting that key questions remain — including where tirzepatide fits in the sequence of treatments doctors typically prescribe.
Perhaps most pointedly, the researchers flagged that scientific promise alone is not enough. Cost, insurance barriers, drug shortages, and side effects that lead patients to stop treatment all stand between the drug's demonstrated potential and the patients it might protect.
A large study of real-world medical records has found that tirzepatide, a diabetes drug sold under the brand name Mounjaro, reduces the risk of major heart attacks and strokes by nearly a third when added to standard treatment for people with type 2 diabetes and existing heart disease. The finding, published in The BMJ, comes from analysis of insurance claims data covering more than 52,000 patients treated between May 2022 and May 2025, offering one of the clearest pictures yet of how the medication performs outside the controlled setting of a clinical trial.
Tirzepatide belongs to a class of drugs called GLP-1 receptor agonists, which have gained attention in recent years for their effects on both blood sugar and weight. While earlier studies had compared tirzepatide to another drug in the same class, dulaglutide, there was less concrete evidence about what happened when doctors added tirzepatide to the medications patients were already taking. This gap left both regulators and clinicians uncertain about when and how to use the drug. The new research was designed to fill that void by comparing tirzepatide against sitagliptin, a different diabetes medication known from prior research to have no particular effect on heart health.
The researchers drew their data from two large US health insurance databases and tracked outcomes for one year after patients started treatment. The group that received tirzepatide numbered 35,353 people; 17,618 received sitagliptin. The average age was 70, and just over half were women. After accounting for differences in age, sex, race, weight, prior heart problems, and other health conditions, the results were striking. Among those taking tirzepatide, 2.9 percent experienced a major cardiovascular event—a heart attack, stroke, or death from any cause. In the sitagliptin group, that figure was 4.4 percent. Translated into practical terms, the researchers calculated that treating 70 patients with tirzepatide would prevent one major cardiovascular event.
When the researchers looked at individual components of that combined outcome, tirzepatide showed a 33 percent reduction in heart attack risk. Stroke, however, showed no meaningful difference between the two groups. The drug also appeared to reduce other serious complications: hospital admissions for infection dropped significantly, as did deaths related to infection and death from any cause. For every 48 patients treated with tirzepatide, one hospitalization for infection was prevented; for every 200 patients, one infection-related death was prevented; and for every 122 patients, one death from any cause was prevented.
The study has limitations that the authors were careful to acknowledge. The follow-up period lasted only one year, which may not capture longer-term effects or risks. There is also the possibility that treatment duration or outcomes were misclassified in the insurance data. The findings may not apply to patients without established heart disease, nor to healthcare systems outside the United States. Because this was an observational study rather than a randomized trial, it cannot definitively prove that tirzepatide caused the improvements—only that they were associated with its use. However, the researchers had previously validated their methods against actual randomized trials, lending credibility to their conclusions.
An accompanying editorial in The BMJ acknowledged the importance of the findings while cautioning that important questions remain unanswered. The study shows what tirzepatide might achieve in routine clinical practice, but it does not establish whether the drug should be a first-line treatment or how it fits into the sequence of medications doctors typically prescribe. The authors called for longer follow-up studies, more rigorous comparisons, and additional research on how tirzepatide works alongside modern standard treatments.
They also raised a practical concern that extends beyond the science itself: even if tirzepatide works, its benefits cannot reach patients if cost, insurance authorization requirements, supply shortages, or side effects cause people to stop taking it. The researchers concluded that while the evidence of cardiovascular benefit is compelling, the question of how best to use the drug in real-world medicine remains open.
Notable Quotes
This study shows how trial-anchored evidence from clinical practice can estimate the expected cardiovascular benefit of initiating tirzepatide beyond standard background treatment and inform shared decision making.— Study authors
Cardiovascular efficacy cannot benefit a population if cost, authorization barriers, supply, and discontinuation prevent sustained treatment.— Study authors
Want the full story?
Read the original at News-Medical ↗
Health & Medicine